Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3437098 | 0.92 | TK1 (0.65) | TK1POLB | |
| SCHEMBL3437095 | 0.92 | TK1 (0.65) | TK1POLB | |
| SCHEMBL25521507 | 0.92 | TK1 (0.65) | TK1POLB | |
| SCHEMBL538835 | 0.92 | TK1 (0.65) | TK1POLB | |
| SCHEMBL538834 | 0.92 | TK1 (0.65) | TK1POLB | |
| Doxribtimine SCHEMBL12296879 | 0.91 | TK1 (0.73) | TK1 | |
| SCHEMBL12352406 | 0.91 | TK1 (0.69) | TK1POLB | |
| Doxribtimine SCHEMBL10382149 | 0.91 | TK1 (0.73) | TK1 | |
| SCHEMBL14063727 | 0.91 | TK1 (0.69) | TK1POLB | |
| SCHEMBL19224119 | 0.91 | TK1 (0.69) | TK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150508-A1 | PHOTO-SWITCHABLE CHEMISTRY FOR REVERSIBLE HYDROGELS AND REUSABLE FLOW CELLS | ILLUMINA, INC. (US) | 2024-05-09 | — | — | US | claimed |
| WO-2024081563-A1 | PHOTO-SWITCHABLE CHEMISTRY FOR REVERSIBLE HYDROGELS AND REUSABLE FLOW CELLS | ILLUMINA, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| WO-2020251933-A1 | COMPOSITIONS COMPRISING FULLERENYL MESOCHLORIN NANO-PHOTOSENSITIZERS WITH COVALENTLY BOUND ANTIBIOTICS AND THEIR USES IN COMBINATION THERAPY | THE UNIVERSITY OF MASSACHUSETTS (US) | 2020-12-17 | — | — | WO | claimed |
| CN-107074911-B | Peptide nucleic acid monomers and oligomers | 优基艾森斯股份公司 | 2020-11-03 | — | — | CN | claimed |
| US-20150080564-A1 | SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS | MARINA BIOTECH, INC. (US) | 2015-03-19 | — | — | US | claimed |
| US-8557982-B2 | Tubulin polymerisation inhibitors | BIONOMICS LIMITED (AU) | 2013-10-15 | — | — | US | claimed |
| WO-2013036868-A1 | SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS | MARINA BIOTECH INC. (US) | 2013-03-14 | — | — | WO | claimed |
| US-20120309768-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | BIONOMICS LIMITED (AU) | 2012-12-06 | — | — | US | claimed |
| US-8278290-B2 | Tubulin polymerisation inhibitors | Biononics Limited (AU) | 2012-10-02 | — | — | US | claimed |
| US-20100292190-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | BIONOMICS LIMITED (AU) | 2010-11-18 | — | — | US | claimed |
| US-6380434-B1 | HYDROXYLATION; AMINATION | SETHNANOTECHNOLOGY, INCORPORATED | 2002-04-30 | — | — | US | claimed |
| US-6303774-B1 | ANTIVIRAL AGENTS, ANTICANCER AGENTS, METABOLIC MODERATORS | SRI INTERNATIONAL | 2001-10-16 | — | — | US | claimed |
| EP-1132380-A1 | E-Isomeric fullerene derivatives | Chiang, Long Y. (TW) | 2001-09-12 | — | — | EP | claimed |
| US-5760013-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | NATIONAL SCIENCE COUNCIL (TW) | 1998-06-02 | — | — | US | claimed |
| EP-0653437-B1 | Process for preparing AZT and derivatives thereof | BRISTOL MYERS SQUIBB CO (US) | 1997-08-13 | — | — | EP | claimed |
| US-5604294-A | IMMUNOSUPRESSIVE, ANTIMICROBIAL, ANTIFUNGAL, ANTIVIRAL, ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE ACTIVITY | ABBOTT LABORATORIES | 1997-02-18 | — | — | US | claimed |
| US-5565555-A | Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues | GILEAD SCIENCES, INC. (US) | 1996-10-15 | — | — | US | claimed |
| US-5194599-A | Forming linkages with nuclosides and nucleotides; viricides, anticarcinogenic agents | GILEAD SCIENCES, INC. (US) | 1993-03-16 | — | — | US | claimed |
| EP-0360609-A2 | Novel hydrogen phosphonodithioate compositions | GILEAD SCIENCES, INC. (US) | 1990-03-28 | — | — | EP | claimed |
| US-4689321-A | CYTOLYSIS, ANTITUMOR, ANTICARCINOGENIC | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1987-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080564-A1 | SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS | POLN, NSUN2, POLM | TK1 617/4885POLB 91/4885 |
| US-20100292190-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | TUBB1, TUBA1C, TUBB | TK1 312/4885POLB 680/4885 |
| US-20120309768-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | TUBB1, TUBA1C, TUBB | TK1 312/4885POLB 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.